Post

Can we overturn the current NHS crisis?

According to the BMA, as of October 2022, 7.21 million NHS patients had had appointments delayed by up to 18 months

Briumvi may struggle to make headway in crowded multiple sclerosis market

While TG Therapeutics is celebrating the approval of Briumvi, its sentiment is not fully shared by KOLs interviewed by GlobalData.

Importance of biomarkers in the ulcerative colitis market

There is a lack of reliable biomarkers that are indicative of outcomes and disease severity for UC patients.

Sanofi offers refunds for Cablivi in novel model for rebates

As risk sharing agreements slowly make their mark, Sanofi’s new Cablivi warranty program presents a newer take on existing methods.

Health Canada accepts Veru’s Covid-19 therapy NDS-CV for review

Proportion of deaths by day 60 was the primary endpoint of the double-blind, randomised, placebo controlled trial.

Finding a cure: How cell and gene therapies could revolutionise medicine

The potential for Advanced Therapy Medicinal Products (ATMPs) is transformational within healthcare, effectively providing the body with the tools to fix itself. ATMPs could offer cures for types of cancer, Alzheimer’s and haemophilia, or even help the patient’s brain to recover from a stroke. We speak to RoslinCT, an internationally recognised innovator in advanced therapeutics, to learn more about the medical breakthroughs under way in Scotland.

Poxel’s PXL770, PXL065 molecules receive EC orphan drug designation

Both PXL770 and PXL065 are currently preparing to enter Phase IIa clinical POC studies.

Money moves: How the biotech market is weathering inflationary storms

Kickstarting the Money Moves series, Pharmaceutical Technology looks at what the biotech market holds for the coming year.

The impact of clinical trial decentralisation on the pharma supply chain

Technological advancement has made decentralised trials more appealing than ever. The pharmaceutical industry must learn to adapt to their growing role

PROTACs show promise for cancer treatment

PROTACs have the potential to revolutionise the way we treat and study a wide range of diseases, by providing a highly specific and targeted means to manipulate the levels of specific proteins within cell.

Moderna’s Covid-19 vaccine sales forecast slashed amidst strong competition

Spikevax is an mRNA vaccine that is approved in 20 geographies including the US, EU, and, the UK.

UTSA researchers to develop compounds for GBM tumours

The researchers’ team is developing compounds that imitate the sex hormone estrogen activity on ER-beta.

Alvotech-Bioventure’s AVT02 approved in Saudi Arabia for manufacturing

AVT02 has already been approved in 27 countries of the EU, Norway, Iceland, Liechtenstein, and the UK.

BioCryst and Swixx BioPharma partner for commercialisation of Orladeyo

Swixx BioPharma will be responsible for commercialising Orladeyo in 15 markets in CEE.

Managing aggressive timelines for clinical trials on a global scale

Sourcing clinical trial products and distributing them in accordance with strict timelines and country-specific regulations can make or break a trial’s success. And with more clinical trials taking place across several countries and within hard-to-reach regions, managing these requirements presents a range of complications for trial sponsors. In this article, Tanner Pharma Group provides insights on clinical trial sourcing and supply and shares their approach to meeting aggressive timelines.

US FDA clears Transcenta’s IND for Rett syndrome treatment

NGN-401 delivers full-length human MECP2 gene using Neurogene’s EXACT gene regulation technology.